-Bloomberg
GT Biopharma Announces Updated Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial An Investigational Immunotherapy For Refractory Cancers To Be Presented at ESMO Congress 2021
GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager,